Inventor · disambiguated record
Shih-Fong Chen
Also filed as: CHEN SHIH-FONG
7 granted patents·3 pending applications·250 citations·filing 1994–2008
88Inventor score
Files withCTRC RES FOUNDATION2UNIV TEXAS2BOREA PIER ANDREA1CANCER THERAPY & RESEARCH CENT1CANCER THERAPY AND RESEARCH CE1
Top patents by PatentIndex Score
10 records- 0183US6004939AMethods for modulation and inhibition of telomeraseCTRC RES FOUNDATION·Filed 1997·Granted Dec 21, 1999·70 cites·16 claims
- 0280US6326390B1Use of adenosine A3 receptor antagonists to inhibit tumor growthKING PHARMACEUTICALS RESEACH A·Filed 1999·Granted Dec 4, 2001·64 cites·39 claims
- 0373US5856096ARapid and sensitive assays for detecting and distinguishing between processive and non-processive telomerase activitiesCTRC RES FOUNDATION·Filed 1995·Granted Jan 5, 1999·54 cites·42 claims
- 0462US6054442AMethods and compositions for modulation and inhibition of telomerase in vitroUNIV TEXAS·Filed 1996·Granted Apr 25, 2000·28 cites·21 claims
- 0558US5561042ADiamine platinum naphthalimide complexes as antitumor agentsCANCER THERAPY AND RESEARCH CE·Filed 1995·Granted Oct 1, 1996·13 cites·2 claims
- 0657US6593306B1Methods for modulation and inhibition of telomeraseUNIV TEXAS·Filed 1999·Granted Jul 15, 2003·18 cites·10 claims
- 0757US2009203719A1Enhancing treatment of mdr cancer with adenosine a3 antagonistsBOREA PIER ANDREA·Filed 2008·Application pending·0 cites
- 0851US2005119289A1Enhancing treatment of MDR cancer with adenosine A3 antagonistsFiled 2003·Application pending·0 cites
- 0949US2004067932A1Enhancing treatment of MDR cancer with adenosine A3 antagonistsFiled 2003·Application pending·0 cites
- 1038US5604095AUnsymmetrically linked bisnaphthalimides as antitumor agentsCANCER THERAPY & RESEARCH CENT·Filed 1994·Granted Feb 18, 1997·3 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when Shih-Fong Chen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →